Exploring GW501516: Benefits, Risks, and Regulatory Status of Cardarine
Dive into an in-depth discussion on GW501516, also known as Cardarine. Learn about its metabolic and performance benefits, health implications, regulatory status, and the risks associated with its misuse.
gw501516
GW501516, also known as Cardarine or Endurobol, is a peroxisome proliferator-activated receptor delta (PPAR-δ) agonist extensively researched for its effects on fat burning, muscle production, endurance enhancement, and potential therapeutic applications. Here are some key points based on research findings:
-
Metabolic and Performance Benefits:
-
Health Implications:
- Although it has shown positive effects on reducing inflammation and improving insulin sensitivity, particularly in high-fructose diet-induced metabolic disturbances2, its development as a therapeutic drug was halted due to its tumorigenic effects observed in clinical trials3.
- Studies suggest anti-cancer properties in certain models, inhibiting cell proliferation and promoting apoptosis in nasopharyngeal carcinoma cells4.
-
Regulatory Status and Risks:
-
Research and Clinical Trials:
Footnotes
-
Pascal Kintz, "Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS," PubMed ↩ ↩2 ↩3
-
D’Angelo C Magliano, "Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice," PubMed ↩ ↩2
-
Martin Weihrauch, "Pharmacological targeting of exercise adaptations in skeletal muscle," NCBI ↩ ↩2
-
Yangyang Ji, "PPARβ/δ Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma," NCBI ↩
-
Pascal Kintz, "Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- δ) and Selective Androgen Receptor Modulator (SARM) Abuse," NCBI ↩
-